Xynomic Pharma, a Delaware-Shanghai oncology drug development company, completed a Series B crossover financing, led by China healthcare investors. Xynomic has announced several in-licensings over the last few years, including a $502 million deal to acquire global rights to a 2nd-generation RAF inhibitor from Boehringer Ingelheim, along with another agreement for its lead drug, Abexinostat. The B round was led by China’s Northern Light Venture Capital, Zhongshan Bison Healthcare Investment and Hakim Unique Internet Company.
Source: China Biotoday
